Skip to content

CONTROLLED STUDY OF TWO COMPONENTS OF FERROUS POLYMOTHERAPY IN THE TREATMENT OF FERROPENIC ANEMIA IN CHILDREN FROM 6 MONTHS TO 2 YEARS OLD

CONTROLLED STUDY OF TWO COMPONENTS OF FERROUS POLYMOTHERAPY IN THE TREATMENT OF FERROPENIC ANEMIA IN CHILDREN FROM 6 MONTHS TO 2 YEARS OLD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-040-04
Enrollment
Unknown
Registered
2004-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Iron A Type of group
elemental iron concentration of 50mg / mL (1 ml dropper = 20 drops) Group name:Iron B Type of group
Elemental iron concentration of 50mg / mL (1 mL dropper = 20 drops)

Sponsors

ABL PHARMA PERU,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. You must have the consent of informed consent. 2. Have an age between 6 months and 2 years. 3. Hemoglobin> 8 and <11 g / dl. and / or decreased serum Ferritin 4. Be able to attend the consultation according to the study schedule. 5. Be included between the 10-90 percentiles, age-statural for age and sex according to the NCHS tables.

Exclusion criteria

Exclusion criteria: 1. History of intolerance to iron salts. 2. History of chronic anemia resistant to treatment. 3. Acute or chronic pathologies that can modify the blood values. 4. Intestinal parasitosis detected by simple direct examination at the time of onset of the study. 5. Need to use medications that can modify the blood values. 6. History of blood discies. 7. History of liver or kidney pathology.

Design outcomes

Primary

MeasureTime frame
Outcome name:Ferritin levels Measure:Ferritin levels achieved at twelve weeks in patients of both groups with pharyngeal polymodal Timepoints:12 weeks

Secondary

MeasureTime frame
Outcome name:Percentage of patients who are withdrawn from the study due to adverse reactions. Measure:Percentage of patients who are withdrawn from the study due to adverse reactions. Timepoints:12 weeks

Countries

Peru

Outcome results

None listed

Source: REPEC (via WHO ICTRP)